• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类恶性黑素瘤细胞系的细胞因子和趋化因子受体模式。

Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines.

机构信息

MTA-DE Public Health Research Group, University of Debrecen, 4032 Debrecen, Hungary.

Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

出版信息

Int J Mol Sci. 2022 Feb 28;23(5):2644. doi: 10.3390/ijms23052644.

DOI:10.3390/ijms23052644
PMID:35269787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8910570/
Abstract

Cytokine and chemokine receptors can promote tumor progression, invasion, and metastasis development by inducing different intracellular signaling pathways. The aim of this study was to determine the cytokine and chemokine receptor gene expression patterns in human melanoma cell lines. We found a large set of cytokine and chemokine receptor genes that were significantly differentially expressed between melanoma cell lines that originated from different subtypes of primary melanomas as well as cell lines that originated from melanoma metastases. The relative expressions of two receptor genes ( and ) were positively correlated with the invasive potential of the cell lines, whereas a negative correlation was observed for the gene expression. We also found a small set of receptor genes that exhibited a significantly decreased expression in association with a mutation. Based on our results, we assume that the analyzed cytokine and chemokine receptor collection may provide potential to distinguish the different subtypes of melanomas, helping us to understand the biological behavior of -mutated melanoma cells.

摘要

细胞因子和趋化因子受体可以通过诱导不同的细胞内信号通路来促进肿瘤的进展、侵袭和转移的发展。本研究的目的是确定人黑色素瘤细胞系中细胞因子和趋化因子受体基因的表达模式。我们发现了一大组细胞因子和趋化因子受体基因,这些基因在起源于不同原发性黑色素瘤亚型的黑色素瘤细胞系以及起源于黑色素瘤转移的细胞系之间存在显著的差异表达。两个受体基因(和)的相对表达与细胞系的侵袭潜能呈正相关,而基因的表达则呈负相关。我们还发现了一小部分受体基因与突变相关表达显著下调。基于我们的结果,我们假设分析的细胞因子和趋化因子受体集合可能有助于区分不同的黑色素瘤亚型,帮助我们了解突变型黑色素瘤细胞的生物学行为。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/cdfd62867902/ijms-23-02644-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/0ef51cbbddce/ijms-23-02644-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/c06cab3005df/ijms-23-02644-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/9525898a9fa5/ijms-23-02644-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/cdfd62867902/ijms-23-02644-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/0ef51cbbddce/ijms-23-02644-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/c06cab3005df/ijms-23-02644-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/9525898a9fa5/ijms-23-02644-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4088/8910570/cdfd62867902/ijms-23-02644-g004.jpg

相似文献

1
Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines.人类恶性黑素瘤细胞系的细胞因子和趋化因子受体模式。
Int J Mol Sci. 2022 Feb 28;23(5):2644. doi: 10.3390/ijms23052644.
2
Gene Expression Changes in Cytokine and Chemokine Receptors in Association with Melanoma Liver Metastasis.细胞因子和趋化因子受体的基因表达变化与黑色素瘤肝转移相关。
Int J Mol Sci. 2023 May 17;24(10):8901. doi: 10.3390/ijms24108901.
3
Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.丝裂原活化蛋白激酶通路在恶性黑色素瘤中的激活可以独立于 BRAF T1799A 突变发生。
Eur J Dermatol. 2010 Sep-Oct;20(5):575-9. doi: 10.1684/ejd.2010.1011. Epub 2010 Jul 7.
4
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.BRAF(V600E)抑制剂PLX4032可增加黑色素瘤细胞中I型胶原蛋白的合成。
Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.
5
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.散发性恶性黑色素瘤中Ras信号通路基因的频繁改变。
Int J Cancer. 2004 Apr 10;109(3):377-84. doi: 10.1002/ijc.11722.
6
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.由BRAF(V600E)突变而非基因扩增所支持的丝裂原活化蛋白激酶活性与黑色素瘤脑转移中的ETV1表达相关。
Arch Dermatol Res. 2014 Dec;306(10):873-84. doi: 10.1007/s00403-014-1490-6. Epub 2014 Jul 30.
7
KIT Suppresses BRAF-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.KIT通过减弱致癌性RAS/MAPK信号传导来抑制BRAF突变型黑色素瘤。
Cancer Res. 2017 Nov 1;77(21):5820-5830. doi: 10.1158/0008-5472.CAN-17-0473. Epub 2017 Sep 25.
8
[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].[携带BRAF或NRAS突变的原发性人类黑色素瘤基因改变的特征分析]
Magy Onkol. 2013 Jun;57(2):96-9. Epub 2013 May 20.
9
Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.BRAF/ERK对Abl激酶的调控及其在黑色素瘤中与Akt的协同作用。
Oncogene. 2017 Aug 10;36(32):4585-4596. doi: 10.1038/onc.2017.76. Epub 2017 Apr 3.
10
Expression of AID in malignant melanoma with BRAF(V600E) mutation.AID在伴有BRAF(V600E)突变的恶性黑色素瘤中的表达。
Exp Dermatol. 2014 May;23(5):347-8. doi: 10.1111/exd.12402.

引用本文的文献

1
Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression.调节性 T 细胞(Tregs)在肿瘤微环境中的复杂作用:其分子机制及其对癌症进展的双向影响。
Int J Mol Sci. 2024 Jul 4;25(13):7346. doi: 10.3390/ijms25137346.
2
Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs.患者匹配的颅内和颅外黑色素瘤转移瘤对之间全基因组基因表达差异的个性化识别与表征。
Acta Neuropathol Commun. 2024 Apr 24;12(1):67. doi: 10.1186/s40478-024-01764-5.
3

本文引用的文献

1
Acid ceramidase controls apoptosis and increases autophagy in human melanoma cells treated with doxorubicin.酸性鞘磷脂酶控制阿霉素处理的人黑色素瘤细胞凋亡和自噬。
Sci Rep. 2021 May 27;11(1):11221. doi: 10.1038/s41598-021-90219-1.
2
CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4.CC 趋化因子在肿瘤中的作用:配体 CCR1、CCR2、CCR3 和 CCR4 的促癌和抗癌特性综述。
Int J Mol Sci. 2020 Nov 9;21(21):8412. doi: 10.3390/ijms21218412.
3
CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation.
Gene Expression Changes in Cytokine and Chemokine Receptors in Association with Melanoma Liver Metastasis.
细胞因子和趋化因子受体的基因表达变化与黑色素瘤肝转移相关。
Int J Mol Sci. 2023 May 17;24(10):8901. doi: 10.3390/ijms24108901.
靶向 CCR2 的胶束用于抗癌肽递药和免疫刺激。
J Control Release. 2021 Jan 10;329:614-623. doi: 10.1016/j.jconrel.2020.09.054. Epub 2020 Oct 1.
4
Current Advances in the Treatment of BRAF-Mutant Melanoma.BRAF 突变型黑色素瘤治疗的当前进展
Cancers (Basel). 2020 Feb 19;12(2):482. doi: 10.3390/cancers12020482.
5
Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers.趋化因子及其受体:在癌症进展中的多方面作用及作为癌症预后标志物的潜在价值
Cancers (Basel). 2020 Jan 24;12(2):287. doi: 10.3390/cancers12020287.
6
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.CCR2 抑制减少肿瘤髓系细胞,并揭示检查点抑制剂的作用以减缓耐药性小鼠脑胶质瘤的进展。
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1129-1138. doi: 10.1073/pnas.1910856117. Epub 2019 Dec 26.
7
DNA hypermethylation is associated with invasive phenotype of malignant melanoma.DNA 高甲基化与恶性黑色素瘤的侵袭表型有关。
Exp Dermatol. 2020 Jan;29(1):39-50. doi: 10.1111/exd.14047. Epub 2019 Nov 14.
8
Cellular Interactions in the Tumor Microenvironment: The Role of Secretome.肿瘤微环境中的细胞相互作用:分泌组的作用
J Cancer. 2019 Aug 7;10(19):4574-4587. doi: 10.7150/jca.21780. eCollection 2019.
9
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.encorafenib 联合 binimetinib 治疗携带 BRAF 突变的不可切除或转移性黑色素瘤。
Expert Rev Clin Pharmacol. 2019 Mar;12(3):259-266. doi: 10.1080/17512433.2019.1570847. Epub 2019 Jan 24.
10
Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.靶向鞘氨醇 1-磷酸轴在 BRAFi 耐药性黑色素瘤中发挥强大的抗肿瘤活性。
Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.